-
1
-
-
62649149433
-
Payer perspectives on pharmacogenomics testing and drug development
-
Epstein RS, Frueh FW, Geren D, Hummer D, McKibbin S, O'Connor S, et al. Payer perspectives on pharmacogenomics testing and drug development. Pharmacogenomics. 2009;10(1):149-51.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.1
, pp. 149-151
-
-
Epstein, R.S.1
Frueh, F.W.2
Geren, D.3
Hummer, D.4
McKibbin, S.5
O'Connor, S.6
-
2
-
-
84870526559
-
Personalized oncology: Recent advances and future challenges
-
Kalia M. Personalized oncology: recent advances and future challenges. Metab Clin Exp. 2013;62 Suppl 1:S11-4.
-
(2013)
Metab Clin Exp
, vol.62
, Issue.SUPPL. 1
-
-
Kalia, M.1
-
3
-
-
78650168711
-
Further opportunities for cost reduction of medical care
-
Malach M, Baumol WJ. Further opportunities for cost reduction of medical care. J Commun Health. 2010;35(6):561-71.
-
(2010)
J Commun Health
, vol.35
, Issue.6
, pp. 561-571
-
-
Malach, M.1
Baumol, W.J.2
-
4
-
-
84871217315
-
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group
-
Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012;15(8):1162-71.
-
(2012)
Value Health
, vol.15
, Issue.8
, pp. 1162-1171
-
-
Faulkner, E.1
Annemans, L.2
Garrison, L.3
Helfand, M.4
Holtorf, A.P.5
Hornberger, J.6
-
5
-
-
84895820950
-
Economic perspectives on personalized health care and prevention
-
Phillips KA, Sakowski JA, Liang S-Y, Ponce NA. Economic perspectives on personalized health care and prevention. Forum Health Econ Policy. 2013;16(2):57-86.
-
(2013)
Forum Health Econ Policy
, vol.16
, Issue.2
, pp. 57-86
-
-
Phillips, K.A.1
Sakowski, J.A.2
Liang, S.-Y.3
Ponce, N.A.4
-
6
-
-
77953315728
-
-
President's Council of Advisors on Science and Technology. Accessed 10 Nov 2013
-
President's Council of Advisors on Science and Technology. Priorities for Personalized Medicine; 2008. http://www.whitehouse.gov/files/documents/ostp/ PCAST/pcast-report-v2.pdf. Accessed 10 Nov 2013.
-
(2008)
Priorities for Personalized Medicine
-
-
-
7
-
-
84856247119
-
-
Accessed 4 Jan 2012
-
Personalized Medicine Coalition. The case for personalized medicine. 3rd ed; 2011. http://www.personalizedmedicinecoalition.org/sites/default/files/ files/Case-for-PM-3rd-edition.pdf. Accessed 4 Jan 2012.
-
(2011)
The Case for Personalized Medicine. 3rd Ed
-
-
-
8
-
-
77951869318
-
Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities
-
Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making. 2010;30(3):328-40.
-
(2010)
Med Decis Making
, vol.30
, Issue.3
, pp. 328-340
-
-
Conti, R.1
Veenstra, D.L.2
Armstrong, K.3
Lesko, L.J.4
Grosse, S.D.5
-
9
-
-
3042819551
-
The role of cost-effectiveness analysis in the era of pharmacogenomics
-
DOI 10.2165/00019053-200422080-00001
-
Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. PharmacoEconomics. 2004;22(8):481-93. (Pubitemid 38858292)
-
(2004)
PharmacoEconomics
, vol.22
, Issue.8
, pp. 481-493
-
-
Flowers, C.R.1
Veenstra, D.2
-
10
-
-
79952363224
-
Points to consider in assessing and appraising predictive genetic tests
-
Rogowski WH, Grosse SD, John J, Kääriäinen H, Kent A, Kristofferson U, et al. Points to consider in assessing and appraising predictive genetic tests. J Commun Genet. 2010;1(4):185-94.
-
(2010)
J Commun Genet
, vol.1
, Issue.4
, pp. 185-194
-
-
Rogowski, W.H.1
Grosse, S.D.2
John, J.3
Kääriäinen, H.4
Kent, A.5
Kristofferson, U.6
-
11
-
-
27644465790
-
Economic analyses of human genetics services: A systematic review
-
DOI 10.1097/01.GIM.0000182467.79495.e2
-
Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med. 2005;7(8):519-23. (Pubitemid 41566478)
-
(2005)
Genetics in Medicine
, vol.7
, Issue.8
, pp. 519-523
-
-
Carlson, J.J.1
Henrikson, N.B.2
Veenstra, D.L.3
Ramsey, S.D.4
-
12
-
-
11044228905
-
A systematic review of cost-effectiveness analyses of pharmacogenomic interventions
-
DOI 10.1517/14622416.5.8.1139
-
Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5(8):1139-49. (Pubitemid 40045254)
-
(2004)
Pharmacogenomics
, vol.5
, Issue.8
, pp. 1139-1149
-
-
Phillips, K.A.1
Van Bebber, S.L.2
-
13
-
-
45749090093
-
Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: A systematic review on content and adherence to guidelines
-
DOI 10.2165/00019053-200826070-00005
-
Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26(7):569-87. (Pubitemid 351871553)
-
(2008)
PharmacoEconomics
, vol.26
, Issue.7
, pp. 569-587
-
-
Vegter, S.1
Boersma, C.2
Rozenbaum, M.3
Wilffert, B.4
Navis, G.5
Postma, M.J.6
-
14
-
-
77957995461
-
Cost effectiveness of pharmacogenomics: A critical and systematic review
-
Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics. 2010;28(11):1001-13.
-
(2010)
PharmacoEconomics
, vol.28
, Issue.11
, pp. 1001-1013
-
-
Wong, W.B.1
Carlson, J.J.2
Thariani, R.3
Veenstra, D.L.4
-
15
-
-
33749155617
-
Genetic screening by DNA technology: A systematic review of health economic evidence
-
DOI 10.1017/S0266462306051221, PII S0266462306051221
-
Rogowski W. Genetic screening by DNA technology. A systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22(3):327-37. (Pubitemid 44469439)
-
(2006)
International Journal of Technology Assessment in Health Care
, vol.22
, Issue.3
, pp. 327-337
-
-
Rogowski, W.1
-
16
-
-
33845487333
-
Current impact of gene technology on healthcare. A map of economic assessments
-
DOI 10.1016/j.healthpol.2006.03.009, PII S0168851006000698
-
Rogowski W. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy. 2007;5(80):340-57. (Pubitemid 44914099)
-
(2007)
Health Policy
, vol.80
, Issue.2
, pp. 340-357
-
-
Rogowski, W.1
-
17
-
-
84902325823
-
-
Accessed 5 Jan 2012
-
National Center for Biotechnology Information. Individualized medicine. 2010. http://www.ncbi.nlm.nih.gov/mesh/68057285. Accessed 5 Jan 2012.
-
(2010)
Individualized Medicine
-
-
-
19
-
-
84902343940
-
-
Medicine UNLo. Accessed 9 Oct 2013
-
Medicine UNLo. What is genetic testing?; 2013. http://ghr.nlm.nih.gov/ handbook/testing/genetictesting. Accessed 9 Oct 2013.
-
(2013)
What Is Genetic Testing?
-
-
-
20
-
-
33947605979
-
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
-
DOI 10.1200/JCO.2006.06.4220
-
Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007;25(6):625-33. (Pubitemid 350002916)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.6
, pp. 625-633
-
-
Liberato, N.L.1
Marchetti, M.2
Barosi, G.3
-
21
-
-
33947584307
-
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
-
DOI 10.1200/JCO.2006.06.3081
-
Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25(6):634-41. (Pubitemid 350002917)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.6
, pp. 634-641
-
-
Kurian, A.W.1
Thompson, R.N.2
Gaw, A.F.3
Arai, S.4
Ortiz, R.5
Garber, A.M.6
-
23
-
-
84902329169
-
-
Accessed 2 Oct 2012
-
Centers for Medicare & Medicaid Services. Draft ICD-10-CM/PCS MS-DRGv28 Definitions Manual. http://www.cms.gov/icd10manual/fullcode-cms/P0001. html. Accessed 2 Oct 2012.
-
Draft ICD-10-CM/PCS MS-DRGv28 Definitions Manual
-
-
-
24
-
-
70349925974
-
30 Years of pharmaceutical cost-utility analyses: Growth, diversity and methodological improvement
-
Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. PharmacoEconomics. 2009;27(10):861-72.
-
(2009)
PharmacoEconomics
, vol.27
, Issue.10
, pp. 861-872
-
-
Neumann, P.J.1
Fang, C.H.2
Cohen, J.T.3
-
25
-
-
84902318962
-
-
Accessed 27 June 2012
-
Organization for Economic Co-operation and Development. 2008 PPP Benchmark results; 2008. http://stats.oecd.org/. Accessed 27 June 2012.
-
(2008)
2008 PPP Benchmark Results
-
-
-
26
-
-
84902317340
-
-
Accessed 27 June 2012
-
Organization for Economic Co-operation and Development. Consumer Prices (MEI); 2012. http://stats.oecd.org/. Accessed 27 June 2012.
-
(2012)
Consumer Prices (MEI)
-
-
-
27
-
-
78650801916
-
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population
-
(Phila)
-
Dinh TA, Rosner BI, Atwood JC, Boland CR, Syngal S, Vasen HF, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila). 2011;4(1):9-22.
-
(2011)
Cancer Prev Res
, vol.4
, Issue.1
, pp. 9-22
-
-
Dinh, T.A.1
Rosner, B.I.2
Atwood, J.C.3
Boland, C.R.4
Syngal, S.5
Vasen, H.F.6
-
28
-
-
77149122082
-
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
-
Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12(2):93-104.
-
(2010)
Genet Med
, vol.12
, Issue.2
, pp. 93-104
-
-
Mvundura, M.1
Grosse, S.D.2
Hampel, H.3
Palomaki, G.E.4
-
29
-
-
79960604164
-
Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis
-
Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
-
(2011)
Ann Intern Med
, vol.155
, Issue.2
, pp. 69-79
-
-
Ladabaum, U.1
Wang, G.2
Terdiman, J.3
Blanco, A.4
Kuppermann, M.5
Boland, C.R.6
-
30
-
-
0142031151
-
An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer
-
DOI 10.1097/01.GIM.0000086626.03082.B5
-
Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med. 2003;5(5):353-63. (Pubitemid 37264984)
-
(2003)
Genetics in Medicine
, vol.5
, Issue.5
, pp. 353-363
-
-
Ramsey, S.D.1
Burke, W.2
Clarke, L.3
-
31
-
-
0035899935
-
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer
-
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 Pt 1):577-88. (Pubitemid 33010193)
-
(2001)
Annals of Internal Medicine
, vol.135
, Issue.8 II
, pp. 577-588
-
-
Ramsey, S.D.1
Clarke, L.2
Etzioni, R.3
Higashi, M.4
Berry, K.5
Urban, N.6
-
32
-
-
0037434418
-
Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
-
DOI 10.1038/sj.bjc.6600630
-
Calvert NW, Morgan AB, Catto JW, Hamdy FC, Akehurst RL, Mouncey P, et al. Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer. 2003;88(1):31-5. (Pubitemid 36241214)
-
(2003)
British Journal of Cancer
, vol.88
, Issue.1
, pp. 31-35
-
-
Calvert, N.W.1
Morgan, A.B.2
Catto, J.W.F.3
Hamdy, F.C.4
Akehurst, R.L.5
Mouncey, P.6
Paisley, S.7
-
33
-
-
0033015788
-
Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2
-
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol. 1999;17(2):494-500. (Pubitemid 29075233)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.2
, pp. 494-500
-
-
Grann, V.R.1
Whang, W.2
Jacobson, J.S.3
Heitjan, D.F.4
Antman, K.H.5
Neugut, A.I.6
-
34
-
-
60349111615
-
Cost-effectiveness of testing for breast cancer susceptibility genes
-
Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health. 2009;12(2):207-16.
-
(2009)
Value Health
, vol.12
, Issue.2
, pp. 207-216
-
-
Holland, M.L.1
Huston, A.2
Noyes, K.3
-
35
-
-
0035958252
-
Policy analysis of cervical cancer screening strategies in low-resource settings: Clinical benefits and cost-effectiveness
-
Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285(24):3107-15. (Pubitemid 32586089)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.24
, pp. 3107-3115
-
-
Goldie, S.J.1
Kuhn, L.2
Denny, L.3
Pollack, A.4
Wright, T.C.5
-
36
-
-
0035899935
-
Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer
-
Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 Part 1):577-88. (Pubitemid 33010193)
-
(2001)
Annals of Internal Medicine
, vol.135
, Issue.8 II
, pp. 577-588
-
-
Ramsey, S.D.1
Clarke, L.2
Etzioni, R.3
Higashi, M.4
Berry, K.5
Urban, N.6
-
37
-
-
84860174889
-
A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy
-
(British Cardiac Society)
-
Ingles J, McGaughran J, Scuffham PA, Atherton J, Semsarian C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart (British Cardiac Society). 2012;98(8):625-30.
-
(2012)
Heart
, vol.98
, Issue.8
, pp. 625-630
-
-
Ingles, J.1
McGaughran, J.2
Scuffham, P.A.3
Atherton, J.4
Semsarian, C.5
-
38
-
-
77957374284
-
Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?
-
Gordon LG, Hirst NG, Young RP, Brown PM. Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness? Cost Eff Resour Alloc. 2010;8:18.
-
(2010)
Cost Eff Resour Alloc
, vol.8
, pp. 18
-
-
Gordon, L.G.1
Hirst, N.G.2
Young, R.P.3
Brown, P.M.4
-
39
-
-
0036962281
-
The cost-effectiveness of interleukin-1 genetic testing for periodontal disease
-
DOI 10.1902/jop.2002.73.12.1474
-
Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. J Periodontol. 2002;73(12):1474-84. (Pubitemid 36131619)
-
(2002)
Journal of Periodontology
, vol.73
, Issue.12
, pp. 1474-1484
-
-
Higashi, M.K.1
Veenstra, D.L.2
Del, A.M.3
Hujoel, P.4
-
40
-
-
84856146284
-
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: Cost-effectiveness and the effect of compliance
-
Retel VP, Joore MA, van Harten WH. Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat. 2012;131(2):627-36.
-
(2012)
Breast Cancer Res Treat
, vol.131
, Issue.2
, pp. 627-636
-
-
Retel, V.P.1
Joore, M.A.2
Van Harten, W.H.3
-
41
-
-
77951938304
-
Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
-
Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer. 2010;46(8):1382-91.
-
(2010)
Eur J Cancer
, vol.46
, Issue.8
, pp. 1382-1391
-
-
Retel, V.P.1
Joore, M.A.2
Knauer, M.3
Linn, S.C.4
Hauptmann, M.5
Harten, W.H.6
-
42
-
-
77952605337
-
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
-
Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist. 2010;15(5):457-65.
-
(2010)
Oncologist
, vol.15
, Issue.5
, pp. 457-465
-
-
Tsoi, D.T.1
Inoue, M.2
Kelly, C.M.3
Verma, S.4
Pritchard, K.I.5
-
43
-
-
79957823551
-
Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer
-
Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manage Care. 2010;16(12):e333-42.
-
(2010)
Am J Manage Care
, vol.16
, Issue.12
-
-
Chen, E.1
Tong, K.B.2
Malin, J.L.3
-
44
-
-
52949084374
-
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan
-
Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat. 2008;112(1):175-87.
-
(2008)
Breast Cancer Res Treat
, vol.112
, Issue.1
, pp. 175-187
-
-
Kondo, M.1
Hoshi, S.L.2
Ishiguro, H.3
Yoshibayashi, H.4
Toi, M.5
-
45
-
-
84863717098
-
Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan
-
Kondo M, Hoshi SL, Ishiguro H, Toi M. Economic evaluation of the 70-gene prognosis-signature (MammaPrint(R)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat. 2012;133(2):759-68.
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.2
, pp. 759-768
-
-
Kondo, M.1
Hoshi, S.L.2
Ishiguro, H.3
Toi, M.4
-
46
-
-
23744459918
-
Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?
-
DOI 10.1097/01.GIM.0000170776.31248.75
-
Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, et al. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med. 2005;7(6):380-9. (Pubitemid 41139621)
-
(2005)
Genetics in Medicine
, vol.7
, Issue.6
, pp. 380-389
-
-
Oestreicher, N.1
Ramsey, S.D.2
Linden, H.M.3
McCune, J.S.4
Van't, V.L.J.5
Burke, W.6
Veenstra, D.L.7
-
47
-
-
79960802694
-
Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer
-
Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TG. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manage Care. 2011;17(7):455-64.
-
(2011)
Am J Manage Care
, vol.17
, Issue.7
, pp. 455-464
-
-
Vanderlaan, B.F.1
Broder, M.S.2
Chang, E.Y.3
Oratz, R.4
Bentley, T.G.5
-
48
-
-
18444374426
-
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
-
Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymphnode-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manage Care. 2005;11(5):313-24. (Pubitemid 40646936)
-
(2005)
American Journal of Managed Care
, vol.11
, Issue.5
, pp. 313-324
-
-
Hornberger, J.1
Cosler, L.E.2
Lyman, G.H.3
-
49
-
-
84863723973
-
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
-
Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat. 2012;133(3):1115-23.
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.3
, pp. 1115-1123
-
-
Lamond, N.W.1
Skedgel, C.2
Rayson, D.3
Lethbridge, L.4
Younis, T.5
-
50
-
-
77954257827
-
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization
-
Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health. 2010;13(4):381-7.
-
(2010)
Value Health
, vol.13
, Issue.4
, pp. 381-387
-
-
Klang, S.H.1
Hammerman, A.2
Liebermann, N.3
Efrat, N.4
Doberne, J.5
Hornberger, J.6
-
51
-
-
84855484712
-
Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer
-
Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012;104(1):56-66.
-
(2012)
J Natl Cancer Inst
, vol.104
, Issue.1
, pp. 56-66
-
-
Hall, P.S.1
McCabe, C.2
Stein, R.C.3
Cameron, D.4
-
52
-
-
58149522113
-
Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa
-
Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112(2):377-83.
-
(2009)
Gynecol Oncol
, vol.112
, Issue.2
, pp. 377-383
-
-
Vijayaraghavan, A.1
Efrusy, M.2
Lindeque, G.3
Dreyer, G.4
Santas, C.5
-
53
-
-
79952789065
-
Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome
-
Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long-QT syndrome. Circ Cardiovasc Qual Outcomes. 2011;4(1):76-84.
-
(2011)
Circ Cardiovasc Qual Outcomes
, vol.4
, Issue.1
, pp. 76-84
-
-
Perez, M.V.1
Kumarasamy, N.A.2
Owens, D.K.3
Wang, P.J.4
Hlatky, M.A.5
-
54
-
-
79957949898
-
Testing women with endometrial cancer to detect Lynch syndrome
-
Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29(16):2247-52.
-
(2011)
J Clin Oncol
, vol.29
, Issue.16
, pp. 2247-2252
-
-
Kwon, J.S.1
Scott, J.L.2
Gilks, C.B.3
Daniels, M.S.4
Sun, C.C.5
Lu, K.H.6
-
55
-
-
51349117705
-
Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis
-
Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis. Thrombosis Haemostasis. 2008;100(3):447-52.
-
(2008)
Thrombosis Haemostasis
, vol.100
, Issue.3
, pp. 447-452
-
-
Smith, K.J.1
Monsef, B.S.2
Ragni, M.V.3
-
56
-
-
34547920290
-
Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations
-
Nielsen M, Hes FJ, Vasen HF, van den Hout WB. Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations. BMC Med Genet. 2007;8:42.
-
(2007)
BMC Med Genet
, vol.8
, pp. 42
-
-
Nielsen, M.1
Hes, F.J.2
Vasen, H.F.3
Van Den Hout, W.B.4
-
57
-
-
58749095297
-
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation
-
Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Int Med. 2009;150(2):73-83.
-
(2009)
Ann Int Med
, vol.150
, Issue.2
, pp. 73-83
-
-
Eckman, M.H.1
Rosand, J.2
Greenberg, S.M.3
Gage, B.F.4
-
58
-
-
73349093096
-
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
-
Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. PharmacoEconomics. 2010;28(1):61-74.
-
(2010)
PharmacoEconomics
, vol.28
, Issue.1
, pp. 61-74
-
-
Meckley, L.M.1
Gudgeon, J.M.2
Anderson, J.L.3
Williams, M.S.4
Veenstra, D.L.5
-
59
-
-
25444513776
-
Pharmacogenetic testing in the clinical management of schizophrenia: A decision-analytic model
-
DOI 10.1097/01.jcp.0000177553.59455.24
-
Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427-34. (Pubitemid 41368364)
-
(2005)
Journal of Clinical Psychopharmacology
, vol.25
, Issue.5
, pp. 427-434
-
-
Perlis, R.H.1
Ganz, D.A.2
Avorn, J.3
Schneeweiss, S.4
Glynn, R.J.5
Smoller, J.W.6
Wang, P.S.7
-
60
-
-
77949874647
-
Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: A pharmacogenetic cost-effectiveness analysis
-
Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125-32.
-
(2010)
Lung
, vol.188
, Issue.2
, pp. 125-132
-
-
Hagaman, J.T.1
Kinder, B.W.2
Eckman, M.H.3
-
61
-
-
70350221662
-
Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy
-
You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin Pharmacol Ther. 2009;86(5):540-7.
-
(2009)
Clin Pharmacol Ther
, vol.86
, Issue.5
, pp. 540-547
-
-
You, J.H.1
Tsui, K.K.2
Wong, R.S.3
Cheng, G.4
-
62
-
-
37349001289
-
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: Potential impact on clinical, patient, and economic outcomes
-
DOI 10.1097/GIM.0b013e318156dd07, PII 0012581720071000000005
-
Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med. 2007;9(10):695-704. (Pubitemid 350287155)
-
(2007)
Genetics in Medicine
, vol.9
, Issue.10
, pp. 695-704
-
-
Veenstra, D.L.1
Harris, J.2
Gibson, R.L.3
Rosenfeld, M.4
Burke, W.5
Watts, C.6
-
63
-
-
58849092406
-
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
-
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health. 2009;12(1):20-7.
-
(2009)
Value Health
, vol.12
, Issue.1
, pp. 20-27
-
-
Carlson, J.J.1
Garrison, L.P.2
Ramsey, S.D.3
Veenstra, D.L.4
-
64
-
-
1542503725
-
HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis
-
DOI 10.1200/JCO.2004.04.158
-
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004;22(5):854-63. (Pubitemid 41103597)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.5
, pp. 854-863
-
-
Elkin, E.B.1
Weinstein, M.C.2
Winer, E.P.3
Kuntz, K.M.4
Schnitt, S.J.5
Weeks, J.C.6
-
65
-
-
34548357288
-
The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: A model-based approach
-
DOI 10.1111/j.1468-1293.2007.00491.x
-
Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L, et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007;8(7):439-50. (Pubitemid 47336785)
-
(2007)
HIV Medicine
, vol.8
, Issue.7
, pp. 439-450
-
-
Yazdanpanah, Y.1
Vray, M.2
Meynard, J.3
Losina, E.4
Weinstein, M.C.5
Morand-joubert, L.6
Goldie, S.J.7
Hsu, H.E.8
Walensky, R.P.9
Dalban, C.10
Sax, P.E.11
Girard, P.M.12
Freedberg, K.A.13
-
66
-
-
68949196334
-
When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study
-
Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227-36.
-
(2009)
Neuropsychopharmacology
, vol.34
, Issue.10
, pp. 2227-2236
-
-
Perlis, R.H.1
Patrick, A.2
Smoller, J.W.3
Wang, P.S.4
-
67
-
-
80053475784
-
KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective
-
Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res. 2011;17(19):6338-46.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.19
, pp. 6338-6346
-
-
Blank, P.R.1
Moch, H.2
Szucs, T.D.3
Schwenkglenks, M.4
-
68
-
-
84865560854
-
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
-
Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850-60.
-
(2012)
Hepatology
, vol.56
, Issue.3
, pp. 850-860
-
-
Camma, C.1
Petta, S.2
Enea, M.3
Bruno, R.4
Bronte, F.5
Capursi, V.6
-
69
-
-
40149108602
-
Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer
-
DOI 10.1093/annonc/mdm488
-
Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19(3):487-95. (Pubitemid 351325669)
-
(2008)
Annals of Oncology
, vol.19
, Issue.3
, pp. 487-495
-
-
Lidgren, M.1
Jonsson, B.2
Rehnberg, C.3
Willking, N.4
Bergh, J.5
-
70
-
-
84870267023
-
Endogenous cost-effectiveness analysis and health care technology adoption
-
Jena AB, Philipson TJ. Endogenous cost-effectiveness analysis and health care technology adoption. J Health Econ. 2013;32(1):172-80.
-
(2013)
J Health Econ
, vol.32
, Issue.1
, pp. 172-180
-
-
Jena, A.B.1
Philipson, T.J.2
-
71
-
-
84865429505
-
A personal view on systems medicine and the emergence of proactive P4 medicine: Predictive, preventive, personalized and participatory
-
Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. Natl Biotechnol. 2012;29(6):613-24.
-
(2012)
Natl Biotechnol
, vol.29
, Issue.6
, pp. 613-624
-
-
Hood, L.1
Flores, M.2
-
72
-
-
33645810425
-
Good practice guidelines for decision-analytic modelling in health technology assessment: A review and consolidation of quality assessment
-
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics. 2006;24(4):355-71.
-
(2006)
PharmacoEconomics
, vol.24
, Issue.4
, pp. 355-371
-
-
Philips, Z.1
Bojke, L.2
Sculpher, M.3
Claxton, K.4
Golder, S.5
-
73
-
-
84902316322
-
-
Rockville
-
Walker DG, Wilson RF, Sharma R, Bridges J, Niessen L, Bass EB, et al. Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. Rockville; 2012.
-
(2012)
Best Practices for Conducting Economic Evaluations in Health Care: A Systematic Review of Quality Assessment Tools
-
-
Walker, D.G.1
Wilson, R.F.2
Sharma, R.3
Bridges, J.4
Niessen, L.5
Bass, E.B.6
-
74
-
-
64549101706
-
Pharmacogenomics and public health
-
Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 2009;12(3):131-3.
-
(2009)
Public Health Genomics
, vol.12
, Issue.3
, pp. 131-133
-
-
Veenstra, D.1
Burke, W.2
-
75
-
-
64549116875
-
Pharmacogenomics, evidence, and the role of payers
-
Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics. 2009;12(3):149-57.
-
(2009)
Public Health Genomics
, vol.12
, Issue.3
, pp. 149-157
-
-
Deverka, P.A.1
-
77
-
-
84877997203
-
Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia
-
Sorich MJ, Wiese MD, O'Shea RL, Pekarsky B. Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. PharmacoEconomics. 2013;31(5):377-91.
-
(2013)
PharmacoEconomics
, vol.31
, Issue.5
, pp. 377-391
-
-
Sorich, M.J.1
Wiese, M.D.2
O'Shea, R.L.3
Pekarsky, B.4
-
78
-
-
79957789708
-
Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses
-
Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA. 2011;305(21):2200-10.
-
(2011)
JAMA
, vol.305
, Issue.21
, pp. 2200-2210
-
-
Ioannidis, J.P.1
Panagiotou, O.A.2
|